Celebrex News and Research

RSS

Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis. It is marketed by Pfizer. It has the brand name Celebrex and Celebra (in other countries) for arthritis and Onsenal for polyps. Celecoxib is available by prescription in capsule form.

FDA's accelerated drug approval process plagued by missing efficacy data and questionable evidence

Since the US Food and Drug Administration established its accelerated approval pathway for drugs in 1992, nearly half of the 253 drugs authorized have not been confirmed as clinically effective, an investigation by The BMJ has found.

31 Jul 2021

Large-scale enhanced recovery program after bariatric surgery improves patient outcomes

A large-scale implementation of a protocol to improve recovery of patients after weight-loss operations was found to reduce rates of extended hospitalization by almost half at 36 participating accredited bariatric surgery centers nationwide, according to a study published online ahead of print in the current issue of the journal Surgery for Obesity and Related Diseases.

24 Sep 2019

Big-data analysis finds new link between popular arthritis drug and heart valve calcification

A well-known, four-year study found popular arthritis drug Celebrex no more dangerous for the heart than older drugs in its same classification - commonly called NSAIDs.

23 Feb 2019

Researchers block common siren call of glioblastoma and metastatic breast cancer

Aggressive cancers like glioblastoma and metastatic breast cancer have in common a siren call that beckons the bone marrow to send along whatever the tumors need to survive and thrive.

23 Jan 2018

New discovery could aid in synthesis of radiotracers for use with PET scanning

Researchers have found a surprisingly versatile workaround to create chemical compounds that could prove useful for medical imaging and drug development.

27 Jul 2017

Arthritis drug increases effectiveness of antidepressants in bipolar patients

Giving severely depressed patients the arthritis drug celecoxib (Celebrex) dramatically boosted the effectiveness of their antidepressant medication, a Loyola study has found.

10 Nov 2016

Common pain and anti-inflammation drugs may slow cancer growth

Scientists from the Florida campus of The Scripps Research Institute have found that one of the most widely prescribed pain and anti-inflammation drugs slows the growth rate of a specific kind of cancer in animal models and suggests the medication could have the same effect on other types of tumors.

26 May 2016

American Pain Society releases new post-surgical pain management guideline

The American Pain Society has released a new evidence-based clinical practice guideline, appearing in The Journal of Pain, with 32 recommendations to help clinicians achieve optimal pain management following surgery. According to numerous studies, the majority of surgical patients receive inadequate pain relief, which can heighten the risk for prolonged post-surgical pain, mood disorders and physical impairment.

18 Feb 2016

Kitov announces more data from Phase III trial on the favorable blood pressure effects of KIT-302

Kitov Pharmaceuticals, an innovative biopharmaceutical company focused on late-stage drug development, today announced more data from its successfully concluded Phase III trial for its lead drug candidate, KIT-302. Data showed the favorable blood pressure effects of KIT-302 were present in all blood pressure variables measured in the study.

18 Dec 2015

Kitov Pharmaceuticals' KIT-302 drug candidate meets primary efficacy endpoint in Phase III clinical trial

Kitov Pharmaceuticals, an innovative biopharmaceutical company focused on late-stage drug development, announced today that the Phase III, double-blind, placebo-controlled clinical trial for its leading drug candidate, KIT-302, successfully met the primary efficacy endpoint of the trial protocol as approved by the U.S. Food & Drug Administration (FDA).

15 Dec 2015

Vitamin D3 and metformin show promising results in preventing colorectal cancer

The concept was simple: If two compounds each individually show promise in preventing colon cancer, surely it's worth trying the two together to see if even greater impact is possible.

24 Mar 2015

Viagra can have anti-cancer, anti-Alzheimer's disease effects if used with new drugs

Chaperone proteins play an important role in protein folding in human cells and in bacteria and are promising new targets for drugs to treat cancer and Alzheimer's disease and for novel antiviral drugs and antibiotics. How existing drugs such as Viagra or Cialis and a derivative of the drug Celebrex, for example, can reduce the activity of a specific chaperone protein, with the potential for anti-tumor and anti-Alzheimer's disease effects, is described in a Review article in DNA and Cell Biology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

10 Mar 2015

New study reveals how COX-2 inhibitors can increase risk of heart attack in arthritis patients

A class of drug for treating arthritis - all but shelved over fears about side effects - may be given a new lease of life, following the discovery of a possible way to identify which patients should avoid using it.

11 Dec 2014

Mylan announces U.S. launch of Celecoxib Capsules

Mylan Inc. today announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions of Pfizer's Celebrex Capsules, which is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults.

10 Dec 2014

Taking NSAIDs with other drugs can increase risk of upper GI bleeding, study finds

Nonsteroidal anti-inflammatory drugs (NSAIDs) - such as ibuprofen and aspirin - increase one's risk of upper gastrointestinal bleeding. When taken in combination with other drugs, this risk is significantly higher, according to new research appearing in the October issue of Gastroenterology, the official journal of the American Gastroenterological Association.

3 Oct 2014

Researchers create combination drug that controls both tumor growth and metastasis

Researchers at UC Davis, University of Massachusetts and Harvard Medical School have created a combination drug that controls both tumor growth and metastasis. By combining a COX-2 inhibitor, similar to Celebrex, and an epoxide hydrolase (sEH) inhibitor, the drug controls angiogenesis (blood vessel formation), limiting a tumor's ability to grow and spread.

14 Jul 2014

U.S. Court awards Teva favorable decision for generic Celebrex

Teva Pharmaceutical Industries Ltd. announced that the U.S. District Court for the Northern District of West Virginia denied a motion filed by Mylan and issued an opinion and order affirming a decision by the FDA under which Teva should receive sole 180-day "first-to-file" exclusivity for generic Celebrex® (celecoxib) 100, 200 and 400 mg capsules.

31 May 2014

Actavis' subsidiary files lawsuit against FDA over Celebrex decision

Actavis plc today announced that its subsidiary, Watson Laboratories, Inc., has filed suit against the U.S. Food and Drug Administration challenging the Agency's decision regarding its entitlement to shared 180-day marketing exclusivity for its generic version of Celebrex (celecoxib) 50 mg, 100 mg, 200 mg and 400 mg capsules.

29 Apr 2014

Mylan challenges FDA's decision regarding generic drug marketing exclusivity on Celecoxib Capsules

Mylan Inc. today announced that it has filed suit against the U.S. Food and Drug Administration, challenging the agency's decision regarding generic drug marketing exclusivity on Celecoxib Capsules, the generic version of Pfizer's Celebrex.

26 Apr 2014

Aspirin can lower colon cancer risk among people with high levels of specific gene

The humble aspirin may have just added another beneficial effect beyond its ability to ameliorate headaches and reduce the risk of heart attacks: lowering colon cancer risk among people with high levels of a specific type of gene.

25 Apr 2014